Towards Personalized Treatment Approaches in Soft Tissue Sarcomas
View More
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric...
January 24, 2025
Register Now!
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Clinical Decision-Making and Sequencing Strategies in EGFR-Mutated NSCLC
January 2nd 2025Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs) vs infusion or subcutaneous therapies, and Dr Scott addressing approaches to sequencing treatments, shared decision-making, and the role of resistance mechanisms and biopsy in guiding therapy decisions for EGFR-mutated advanced non–small cell lung cancer (NSCLC).
Managing Dermatologic Toxicities with EGFR Targeted Therapies in NSCLC
January 2nd 2025Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral antibiotics and topical treatments, and patient education about self-management strategies.
Practical Adverse Management Strategies With Intravenous Amivantamab
December 23rd 2024Panelists discuss how venous thromboembolism risk assessment and prophylaxis decisions in patients with non–small cell lung cancer require careful consideration of individual risk factors, patient education strategies, and balanced communication about the benefits and concerns of preventive measures, particularly in the context of amivantamab therapy.
Optimizing EGFR-Targeted Therapy in NSCLC: Practical Management Strategies for Nurses and Physicians
December 23rd 2024Panelists discuss how adverse event profiles, management strategies, and patient education approaches differ among EGFR-targeted therapies for non–small cell lung cancer, including oral tyrosine kinase inhibitors like osimertinib and infusion therapies like amivantamab, with emphasis on monitoring requirements and treatment sequencing decisions.
Subcutaneous Amivantamab in Practice: Clinical Insights and AE Management
December 23rd 2024Panelists discuss how the availability of subcutaneous amivantamab influences nursing approaches to patient care and education, with Squires sharing strategies for ensuring patients understand the new administration method and preparing them for treatment.
EGFR-Targeted Therapies in NSCLC: IV vs Subcutaneous Administration
December 23rd 2024Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Dr Scott highlighting its potential clinical benefits, while Squires shares insights on managing the adverse event profile and strategies for managing adverse effects in patients receiving intravenous (IV) amivantamab.